Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Lysosomal Storage Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for NEU1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | NEU1 Recombinant Protein (HEK293 expressed, C-terminal His-Tag). High purity (>95%), Endotoxin controlled (<1.0 EU/μg). Sequence Verified. Designed for enzyme activity assays and antibody screening. | View NEU1 Products |
| Gene Delivery | NEU1 Promise-ORF / Lentivirus. Full-length human NEU1 ORF for stable cell line generation. Ideal for studying cell-surface sialidase activity and receptor desialylation. | View NEU1 Products |
| Benchmark Ab | Anti-NEU1 Recombinant Monoclonal Antibody. Recombinant positive control for flow cytometry, ELISA, and western blot assays. | View NEU1 Products |
| Validator | NEU1 siRNA Set. Three target-specific siRNAs for transient knockdown verification in functional assays. | View NEU1 Products |
| Related Target A | CTSA (Cathepsin A / PPCA). Essential protective protein that forms a stable complex with NEU1, preventing its rapid degradation and restoring lysosomal sialidase activity. | View CTSA Products |
| Related Target B | NEU3 (Sialidase 3). Plasma membrane-bound sialidase. Crucial counter-screening target to ensure selectivity of small-molecule NEU1 inhibitors. | View NEU3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Dependency on CTSA for functional stability | High-purity CTSA co-proteins available to reconstitute active sialidase complexes in vitro. |
| Sialidase subfamily counter-screening (NEU1 vs NEU3/NEU4) | Homolog panel proteins strictly verified by mass spectrometry to guarantee sequence identity and eliminate cross-contamination. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives in Sialidase Activity | Validated siRNA included for specificity checks |
Live NEU1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of NEU1 (Sialidase-1) is rapidly gaining traction as its dual role in lysosomal storage disorders (such as Sialidosis) and oncology becomes increasingly clear. In cancer biology, cell-surface NEU1 regulates the sialylation state of key receptor tyrosine kinases (RTKs) like EGFR and PDGFR, as well as immune checkpoints. The race for NEU1 therapeutics is intensifying, with major players shifting focus from traditional enzyme replacement therapies (ERT) to highly selective small-molecule inhibitors and targeted biologics. As first-generation therapies reach the clinic, the next wave of R&D is targeting tumor-specific cell surface sialidase activity to block metastatic signaling pathways.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Consortia, Biotech Startups | Oncology (Metastasis inhibition), Fibrosis | Selectivity Assay (Need Mutant vs WT Proteins and Sialidase homolog panels) |
| Enzyme Replacement (ERT) | Lysosomal Disease Specialists | Sialidosis Type I & II | Complex Assembly Validation (Need high-purity NEU1 and CTSA proteins) |
| Monoclonal Antibodies | Biopharma Innovators | Inflammatory Diseases, Cancer | Conformational Binding Assay (Need Lentivirus for Stable Cell Line development) |